Agilent RapidFire High-throughput MS
RapidFire technology uses innovative microfluidics for an SPE-based MS solution, enabling detection of native compounds. RapidFire MS is 10 to 100 times faster than conventional MS screening methods. Requiring no labels or surrogates, RapidFire enables the screening of intractable or challenging targets which are not amenable to fluorescence or luminescence.
Available as hardware for your lab or as a contract research service, Agilent's RapidFire technology provides life science researchers with shortened time to results, accurate data and greater potential for success.
Reviews
No reviews to display
Latest Videos
Latest news
News
Agilent Technologies and Ameritox Form Collaboration, Aim to Advance Analysis of Medication Monitoring
11 Feb 2013
-
RapidFire to be Featured in Pharma Clinical Research Track at Agilent User Event
31 May 2011
-
BIOCIUS Life Sciences Expands Contract Research Service with New ADME Assay Analysis
05 Jan 2011
-
Fully-Validated SIRT1 Enhances Drug Discovery Investigation
07 Jul 2010
-
BIOCIUS Life Sciences and BlueSky Biotech Extend Partnership, Provide Validated Enzymes
15 Jun 2010
Application articles
-
Fragment-Based Drug Discovery: Comparing Labeled and Label-Free Screening of β-Amyloid Secretase (BACE-1) Using Fluorescence Spectroscopy and Ultrafast SPE/MS/MS
Agilent RapidFire High-throughput MS13 Feb 2013
-
High-Throughput Lead Discovery for the Analysis of Acetyl-Coenzyme A Carboxylase (ACC)
Agilent RapidFire High-throughput MS11 Jan 2012
-
High-Throughput MS Detection of Histone H3 Demethylation by Lysine-Specific Demethylase 1 (LSD1)
Agilent RapidFire High-throughput MS07 Jan 2012
-
High-Throughput In Vitro ADME Analysis with Permeability Assays
Agilent RapidFire High-throughput MS05 Jan 2012
-
HT Analysis of Epigenetic Targets
Agilent RapidFire High-throughput MS03 Jan 2012
